4 European Projects Found
Searched on 125080 European Projects
FINISHED
Molecular Mechanisms of Fungal Pathogen Host Interactions (ImResFun)
Start date: Oct 1, 2013, End date: Sep 30, 2017,
ImResFun shall provide state-of-the-art training in infectious disease research and medical immunology targeting the most common human fungal pathogens, the opportunistic Candida species. The key objectives of ImResFun are: (i) to understand how immune cells and infected organs respond to invasion by Candida spp, (ii) to decipher host-defense mechanisms mediating pathogen elimination, and (iii) to ...
Read Project
12
Partners Participants
FINISHED
Nanotechnology based cochlear implant with gapless interface to auditory neurons (NANOCI)
Start date: Sep 1, 2012, End date: Aug 31, 2015,
Over 60 million of citizens in the EU suffer from hearing loss with its associated restrictions. In severe cases, hearing can only be restored by surgically implanting a neuroprosthesis called cochlear implant, which directly stimulates the auditory nerve.The bottleneck for optimal stimulation is caused by the anatomical gap between the electrode array and the auditory neurons in the inner ear. As ...
Read Project
9
Partners Participants
FINISHED
Infectious triggers of chronic autoimmunity (INTRICATE)
Start date: Nov 1, 2010, End date: Apr 30, 2015,
This proposal builds on existing expertise and collaborations of a multidisciplinary Consortium of basic scientists and clinical investigators each of whom has made a substantial individual contribution to understanding the links between infection and autoimmunity. The aim of the INTRICATE Consortium is to prosecute a programme of Translational Research that deliniates the role of infection in the ...
Read Project
13
Partners Participants
FINISHED
Highly efficient new generation synthetic RNA-replicon based vaccine (Replixcel)
Start date: Apr 1, 2010, End date: Mar 31, 2014,
The project seeks to create a novel, efficacious vaccine against influenza virus; a new type of synthetic vaccine readily adaptable to meet whichever influenza virus subtype may arise. A new generation of RNA-replicon technology will be employed combined with nanoparticles and innovative adjuvants for targeting of dendritic cells and efficient antigen expression. The consortium comprises two SMEs ...
Read Project
